Campbell & Co Investment Adviser’s Catalyst Pharmaceutical CPRX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-37,706	Closed	-$934K	–	1087
2026 Q1	$934K	Buy	+37,706	New	+$898K	0.05%	530
2025 Q4	–	Sell	-97,840	Closed	-$1.93M	–	1167
2025 Q3	$1.93M	Buy	97,840 +54,299	+125%	+$1.12M	0.15%	197
2025 Q2	$945K	Sell	43,541 -51,538	-54%	-$1.22M	0.06%	527
2025 Q1	$2.31M	Buy	+95,079	New	+$2.14M	0.18%	155
2024 Q2	–	Sell	-19,202	Closed	-$306K	–	1086
2024 Q1	$306K	Buy	+19,202	New	+$289K	0.03%	897
2023 Q2	–	Sell	-31,721	Closed	-$526K	–	924
2023 Q1	$526K	Sell	31,721 -28,188	-47%	-$465K	0.1%	399
2022 Q4	$1.11M	Sell	59,909 -12,653	-17%	-$195K	0.27%	80
2022 Q3	$931K	Sell	72,562 -81,805	-53%	-$969K	0.21%	144
2022 Q2	$1.08M	Buy	154,367 +18,986	+14%	+$139K	0.29%	65
2022 Q1	$1.12M	Buy	135,381 +59,181	+78%	+$418K	0.3%	61
2021 Q4	$516K	Buy	76,200 +44,500	+140%	+$293K	0.18%	188
2021 Q3	$168K	Sell	31,700 -11,200	-26%	-$61.2K	0.05%	540
2021 Q2	$247K	Buy	+42,900	New	+$221K	0.1%	381

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Campbell & Co Investment Adviser's CPRX Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 37,706 shares — an estimated $934K sold.

Campbell & Co Investment Adviser first reported a position in CPRX in Q2 2021 and held it in 13 quarters. The position peaked at $2.31M in Q1 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Campbell & Co Investment Adviser reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 37,706 Catalyst Pharmaceutical shares in Q2 2026, an estimated $934K.
Campbell & Co Investment Adviser first reported a position in Catalyst Pharmaceutical in Q2 2021 and held it in 13 quarters.
Campbell & Co Investment Adviser's Catalyst Pharmaceutical position peaked at $2.31M in Q1 2025.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.